As shares tank, Or­chard once again re­struc­tures, shed­ding gene ther­a­py pro­grams and a large part of the staff

Al­most ex­act­ly 2 years ago, Or­chard Ther­a­peu­tics ex­ecs re­or­ga­nized the pipeline, shed staff and cir­cled their wag­ons around what they con­sid­ered the most vi­tal part of its R&D ef­fort. To­day, they’re go­ing back in to cut again, tak­ing out once key pro­grams while des­ig­nat­ing a new line­up as es­sen­tial to its fu­ture.

Or­chard, a UK/US hy­brid gene ther­a­py com­pa­ny, is tak­ing the ax to ther­a­pies for rare pri­ma­ry im­mune de­fi­cien­cies. These in­clude: OTL-103 for Wiskott-Aldrich syn­drome, OTL-102 for X-linked chron­ic gran­u­lo­ma­tous dis­ease and Strimvelis, a gam­maretro­vi­ral vec­tor-based gene ther­a­py ap­proved in Eu­rope for adeno­sine deam­i­nase se­vere com­bined im­mun­od­e­fi­cien­cy (ADA-SCID).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER